Can you guess the (lightly disputed) champion of healthcare AI suppliers? Here’s a hint. This company caters to physicians and just this week reached a valuation of $12B. 

The American Academy of Pediatrics and co-plaintiffs are tightening the screws in their lawsuit against HHS Secretary Robert F. Kennedy Jr. and other healthcare leaders in the Trump administration.   

2026 may be the year that many if not most healthcare leaders arrive at a fork in the road to mature AI implementation. 

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

Where have the missing rural American hospitals gone? And where is rural healthcare headed? The discussion is on in Washington and elsewhere.  

Just because a healthcare AI product gets loudly promoted doesn’t mean its claims are bogus. The salient question is whether or not it performs as well in a clinical setting as it did in a research lab—or in a marketer’s mind. 

President Trump’s outline is largely an exercise in thinking out loud since it can’t propel anything consequential without legislative action in Congress. Still, the plan—and the reactions it’s eliciting—warrant a look. 

TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?